#United States #None #Medtronic #Hugo™ Robotic #Surgery System

Medtronic Expands Hugo™ Surgical System in the U.S.

Medtronic, a renowned name in healthcare technology, has made significant advancements toward expanding its Hugo™ robotic-assisted surgery system's applications in the United States. Recently, the company submitted key 510(k) filings that aim to bring the groundbreaking technology to both general and gynecologic surgical specialties. This initiative not only marks a milestone for Medtronic but also promises to reshape the landscape of surgical options available to healthcare providers and patients alike.

Major Milestones Achieved

Among the notable achievements listed in the recent announcements are:

• - Submission of 510(k) clearance for the Hugo™ system's application in general surgery, particularly for hernia repairs.
• - Successful completion of patient enrollment for the Embrace Gynecology Investigational Device Exemption (IDE) clinical study aimed at assessing the Hugo™ system's effectiveness in gynecologic surgeries.
• - Additional 510(k) approvals have been submitted for the LigaSure™ RAS Maryland instrument, specifically designed for the Hugo™ system.
• - FDA clearance has been granted for ProGrip™ Advanced mesh, enhancing its usage in robotic-assisted ventral hernia repair procedures.

These developments reflect Medtronic's commitment to enriching surgical care and expanding robotic options amidst an increasing demand for minimally invasive surgical solutions.

Enhancing Surgical Capabilities

The introduction of the Hugo™ system into general surgery and gynecology not only broadens its clinical applications but also addresses the rising preference among patients and surgeons for robotic-assisted surgeries. The data highlights that the Hugo™ system has been a subject of extensive use globally, with more than 35 countries adopting the system, performing tens of thousands of procedures. This innovative platform has garnered trust among medical professionals, supported by a wealth of scientific literature advocating its effectiveness and safety.

Matt Anderson, senior vice president of Medtronic’s Surgical business, expressed that this isn’t merely a portfolio expansion but part of their genuine commitment to unify instruments, intelligence, and human expertise into an integrated surgical ecosystem. This visionary approach aims to make superior surgical options accessible to every patient, thereby enhancing surgical outcomes and experiences.

Key Technologies Backing the System

To further solidify the capabilities of the Hugo™ system, the newly submitted LigaSure™ RAS Maryland instrument has been tailored for use with the Valleylab™ FT10 energy platform. This cutting-edge technology boasts over 35 million procedures globally, signifying its reliability and efficiency in enhancing critical procedure moments.

Dr. Matthew Kroh, the chief medical officer at Medtronic and a practicing surgeon, stated that integrating the LigaSure technology into the Hugo™ system provides surgeons with enhanced confidence and control. The growing demand for robotic-assisted procedures necessitates improved access to technology and comprehensive training, which Medtronic is poised to deliver effectively.

Additionally, the ProGrip™ Advanced mesh showcases a progressive evolution in mesh design aimed at tackling the unique requirements of robotic-assisted ventral hernia repairs. With ProGrip technology already featured in over 6 million procedures, the new advanced version offers heightened efficiency in robotic operations, emphasizing easier insertion and handling compared to earlier alternatives.

Embrace Gynecology Study Enrollment Completed

The company has also completed enrollment for the Embrace Gynecology IDE study, involving 70 patients across five medical facilities in the U.S. This extensive trial is aimed at evaluating the Hugo™ system's safety and efficacy in robotic-assisted gynecologic procedures, a significant step toward broader acceptance and integration of robotic technologies in gynecological practices.

In summary, with these new filings and approvals, Medtronic is taking substantial steps to widen the adoption of the Hugo™ robotic-assisted surgery system and enhance surgical practices across the U.S. This initiative is a testament to Medtronic’s unwavering commitment to innovation, improved patient outcomes, and the integration of advanced technologies within surgical environments. For further details, please visit medtronic.com/hugoishere.

Conclusion

As Medtronic continues to pioneer advancements in robotic surgery, the collaborative effort to align technology with user needs will be paramount. By embracing these innovations in general surgery and gynecology, Medtronic is ensuring the future of surgical care is not only efficient but also adaptable to the evolving landscape of healthcare demands.